Watch Live

Tweet TWEET

Healthcare Companies Report FDA Approvals, Comprehensive Analysis, Schedules, and Stock Movements - Analyst Notes on Pfizer,

Healthcare Companies Report FDA Approvals, Comprehensive Analysis, Schedules,   and Stock Movements - Analyst Notes on Pfizer, Johnson & Johnson, Biogen,                    Express Scripts, and Forest Laboratories  Editor Note: For more information about this release, please scroll to bottom.  PR Newswire  NEW YORK, March 20, 2014  NEW YORK, March 20, 2014 /PRNewswire/ --  Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), Biogen Idec Inc. (NASDAQ: BIIB), Express Scripts Inc. (NASDAQ: ESRX), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register  --  PfizerInc.AnalystNotes  On March 14, 2014, Pfizer Inc. (Pfizer), along with the Bristol-Myers Squibb Company, reported that the U.S. Food and Drug Administration (FDA) has provided an approval on a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. Commenting on the release, Steven J. Romano, M.D., Senior Vice President and Medicines Development Group Head, stated, "As the number of hip and knee replacement surgeries performed in the U.S. continues to increase, the risk of DVT following these surgeries remains a concern for physicians. Eliquis provides patients and physicians with a new treatment option that offers twice daily oral dosing and no routine coagulation testing, and is broadly accessible through hospitals and managed health care formularies." The full analyst notes on Pfizer Inc. are available to download free of charge at:  http://www.AnalystsReview.com/03202014/PFE/report.pdf  --  Johnson&JohnsonAnalystNotes  On March 11, 2014, Johnson & Johnson announced that Dominic Caruso, Vice President, Finance and CFO, along with Louise Mehrotra, Vice President, Investor Relations, will host the Company's conference call for investors on April 15, 2014, at 8:30 a.m. ET. According to the release, Caruso and Mehrotra will review the Company's Q1 2014 results. Additionally, the Company stated that interested parties may access a live webcast of the conference call, which is optimized for mobile streaming on iOS devices, on the Johnson & Johnson Investor Relations website as well as a podcast replay (available approximately two hours after the conference call). The full analyst notes on Johnson & Johnson are available to download free of charge at:  http://www.AnalystsReview.com/03202014/JNJ/report.pdf  --  BiogenIdecInc.AnalystNotes  On March 17, 2014, Biogen Idec Inc.'s (Biogen) stock went up by 4.04%, at $345.60 per share. Over the past one-month trading period, Biogen's stock went up by 5.27%, outperforming the Nasdaq Composite which went up by 0.85% during the same one-month trading period. The full analyst notes on Biogen Idec Inc. are available to download free of charge at:  http://www.AnalystsReview.com/03202014/BIIB/report.pdf  --  ExpressScriptsInc.AnalystNotes  On March 12, 2014, Express Scripts Inc. (Express Scripts) announced that according to its most current and comprehensive analysis of Attention Deficit Hyperactivity Disorder (ADHD) medication, the number of Americans who use medication to treat ADHD rose 36% in five years, reaching a total of more than 4.8 million privately insured individuals in 2012. According to Express Scripts, the TurningAttentiontoADHD report shows that during the five-year study the greatest increase of medication usage was among adults with the largest usage increase of 85%, seen in women ages 26-34. Commenting on the release, David Muzina, M.D., Company Vice President of Specialist Practice, stated, "While generally safe for the majority of the population of patients, ADHD medications require judicious prescribing. Our clinical programs and model of specialized pharmacy practice, which includes neuroscience and behavioral health, provide an important safety net for patients who may be struggling with side effects from ADHD drugs, as well as additional mental disorders that can complicate their care." The full analyst notes on Express Scripts Inc. are available to download free of charge at:  http://www.AnalystsReview.com/03202014/ESRX/report.pdf  --  ForestLaboratoriesInc.AnalystNotes  On March 17, 2014, Forest Laboratories Inc.'s (Forest Laboratories) stock declined by 0.27%, closing at $95.25 per share. For the past six-month trading period, Forest Laboratories' shares reflected a significant increase of 113.57%, compared to the Dow Jones Industrial Average which went up by 4.62%, during the same trading period. The full analyst notes on Forest Laboratories Inc. are available to download free of charge at:  http://www.AnalystsReview.com/03202014/FRX/report.pdf  --  AboutAnalystsReview We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.  --  =============  EDITORNOTES:    oThis is not company news. We are an independent source and our views do     not reflect the companies mentioned.   oInformation in this release is fact checked and produced on a best efforts     basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are     only human and are prone to make mistakes. If you notice any errors or     omissions, please notify us below.   oThis information is submitted as a net-positive to companies mentioned, to     increase awareness for mentioned companies to our subscriber base and the     investing public.   oIf you wish to have your company covered in more detail by our team, or     wish to learn more about our services, please contact us at pubco [at]     AnalystsReview.com.   oForanyurgentconcernsorinquiries, please contact us at compliance     [at] AnalystsReview.com.   oAre you a public company? Would you like to see similar coverage on your     company? Send us a full investors' package to research [at]     AnalystsReview.com for consideration.  COMPLIANCEPROCEDURE  Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.  NOTFINANCIALADVICE  Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.  NOWARRANTYORLIABILITYASSUMED  Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.  CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.  SOURCE Analysts Review  Contact: CONTACT PERSON: Adam Redford CONTACT PHONE: +852-8191-3972